FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
Executive Summary
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].
You may also be interested in...
Follow-on Biologics Base Camp: Senate Has Four Rival Proposals
Brand biologics fare well in the amendments prepared for the HELP Committee mark-up, as even Sen. Brown offers at least seven years of exclusivity.
FTC's Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban
The Federal Trade Commission has drawn another arrow in its attempt to shoot down reverse settlements between brand and generic drug companies - offering an estimate of $12 billion in government savings over the next 10 years from ending the practice
FTC's Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban
The Federal Trade Commission has drawn another arrow in its attempt to shoot down reverse settlements between brand and generic drug companies - offering an estimate of $12 billion in government savings over the next 10 years from ending the practice